Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation

References

Page 1

	Year	Citations
British National Formulary Journal of the American Pharmaceutical Association (Scientific ed ) British National FormularyStandardizationSpecification (Technical Standard)	1958	2.5K
Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation David C. Lowance, Hans-H. Neumayer, Christophe Legendre, New England Journal of Medicine	1999	712
LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTS P. Stephen Almond, Arthur J. Matas, Kristen J. Gillingham, Transplantation	1993	675
Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant Recipients David R. Snydman, Barbara G. Werner, Beverly Heinze-Lacey, New England Journal of Medicine Cytomegalovirus Immune GlobulinCytomegalovirus DiseaseImmunologyRenal-transplant RecipientsImmunotherapy	1987	581
A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts Henry H. Balfour, Beverly A. Chace, Jack T. Stapleton, New England Journal of Medicine	1989	541
THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG-TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2 ARTHUE J. MATAS, Kristen J. Gillingham, William D. Payne, Transplantation	1994	446
Applied therapeutics; the clinical use of drugs General Pharmacology The Vascular System Clinical TherapeuticMedicineTherapeutic AreaPharmacotherapyPharmacology	1990	402
THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTS Avinash C. Gulanikar, Allan S. MacDonald, Uğur Sungurtekin, Transplantation Transplant RejectionFirst YearUrologyTransplantationKidney Transplant	1992	196
CYTOMEGALOVIRUS INFECTION—AN ETIOLOGICAL FACTOR FOR REJECTION? A PROSPECTIVE STUDY IN 242 RENAL TRANSPLANT PATIENTS Claire Pouteil‐Noble, René Écochard, G. Landrivon, Transplantation	1993	181
PROPHYLACTIC ORAL GANCICLOVIR COMPARED WITH DEFERRED THERAPY FOR CONTROL OF CYTOMEGALOVIRUS IN RENAL TRANSPLANT RECIPIENTS1,2,??? Daniel C. Brennan, Kathy A. Garlock, Gary G. Singer, Transplantation	1997	155

Page 1